Retreatment of hepatitis C patients with pegylated interferon combined with ribavirin in non-responders to interferon plus ribavirin. Is it different in real life?-Reference-Cited by-同舟云学术

Retreatment of hepatitis C patients with pegylated interferon combined with ribavirin in non-responders to interferon plus ribavirin. Is it different in real life?

Published:2010-07-20 Issue:1 Volume:10 Page:
ISSN:1471-2334
Container-title:BMC Infectious Diseases
language:en
Short-container-title:BMC Infect Dis

Author:

Gonçales Fernando L,Moma Camila A,Vigani Aline G,Angerami Adriana FCF,Gonçales Eduardo SL,Tozzo Raquel,Pavan Maria HP,Gonçales Neiva SL

Publisher

Springer Science and Business Media LLC

Subject

Infectious Diseases

Link

http://link.springer.com/article/10.1186/1471-2334-10-212/fulltext.html

Reference10 articles.

1. Manns M, McHutchinson J, Gordon SC, Rustgi VK, Shiffman M, Reindollar R, Goodman ZD, Koury K, Ling M, Albrecht JK: Peg-interferon alfa -2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet. 2001, 358: 958-65. 10.1016/S0140-6736(01)06102-5.

2. Fried MW, Shiffman ML, Reddy KR, Smith C, Marinos G, Gonçales FL, Haussinger D, Diago M, Carosi G, Dhumeaux D, Craxi A, Lin A, Hoffman J, Yu J: Peginterferon alfa-2a plus ribavirin for chronic hepatitis virus infection. N Eng J Med. 2002, 347: 975-982. 10.1056/NEJMoa020047.

3. Hadziyannis SJ, Sette H, Morgan TR: Peginterferon alfa-2a (40 kilodaltons) and ribavirin combination therapy in chronic hepatitis C: randomized study of the effect of treatment duration and ribavirin dose. Ann Intern Med. 2004, 140: 346-355.

4. Parise E, Cheinquer H, Crespo D, Meirelles A, Martinelli A, Sette H, Gallizi J, Silva R, Lacet C, Correa E, Cotrim H, Fonseca J, Paraná R, Spinelli V, Amorim W, Tatsch F, Pessoa M, Brazilian Pegasys Cooperative Study Group: Peginterferon alfa- 2 a(40 KD) (PEGASYS®) plus Ribavirin (COPEGUS®) in retreatment of chronic hepatitis C patients nonresponders and relapsers to previous conventional interferon plus ribavirin therapy. Braz J Infect Dis. 2006, 10: 11-16.

5. Shiffman ML, Di Bisceglie AM, Lindsay KL, Morishima C, Wright EC, Everson GT, Lok AS, Morgan TR, Bonkovsky HL, Lee WM, Dienstag JL, Ghany MG, Goodman ZD, Everhart JE, The Halt-C Trial Group: Peginterferon alfa-2a and ribavirin in patients with chronic hepatitis C who have failed prior treatment. Gastroenterology. 2004, 126: 1015-1023. 10.1053/j.gastro.2004.01.014.

Cited by 8 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The efficacy of paritaprevir/ritonavir/ombitasvir+dasabuvir and ledipasvir/sofosbuvir is comparable in patients who failed interferon-based treatment with first generation protease inhibitors - a multicenter cohort study;BMC Infectious Diseases;2018-11-16

2. KASL clinical practice guidelines: management of hepatitis C;Clinical and Molecular Hepatology;2016-03-28

3. Costs and outcomes of treating chronic hepatitis C patients in routine care - results from a nationwide multicenter trial;Journal of Viral Hepatitis;2015-09-28

4. EFFICACY OF TREATMENT WITH PEGYLATED INTERFERON AND RIBAVIRIN IN PATIENTS WITH CHRONIC HCV INFECTION “UNDER REAL LIFE“ CONDITIONS;Medicinos teorija ir praktika;2014-12-20

5. KASL clinical practice guidelines: Management of Hepatitis C;Clinical and Molecular Hepatology;2014